RT Journal Article
SR Electronic
T1 From first to second wave: follow-up of the prospective Covid-19 cohort (KoCo19) in Munich (Germany)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.27.21256133
DO 10.1101/2021.04.27.21256133
A1 Katja Radon
A1 Abhishek Bakuli
A1 Peter Pütz
A1 Ronan Le Gleut
A1 Jessica Michelle Guggenbuehl Noller
A1 Laura Olbrich
A1 Elmar Saathoff
A1 Mercè Garí
A1 Yannik Schälte
A1 Turid Frahnow
A1 Roman Wölfel
A1 Michael Pritsch
A1 Camilla Rothe
A1 Michel Pletschette
A1 Raquel Rubio-Acero
A1 Jessica Beyerl
A1 Dafni Metaxa
A1 Felix Forster
A1 Verena Thiel
A1 Noemi Castelletti
A1 Friedrich Rieß
A1 Maximilian N. Diefenbach
A1 Günter Fröschl
A1 Jan Bruger
A1 Simon Winter
A1 Jonathan Frese
A1 Kerstin Puchinger
A1 Isabel Brand
A1 Inge Kroidl
A1 Andreas Wieser
A1 Michael Hoelscher
A1 Jan Hasenauer
A1 Christiane Fuchs
A1 on behalf of the KoCo19 study group
YR 2021
UL http://medrxiv.org/content/early/2021/04/29/2021.04.27.21256133.abstract
AB Background In the 2nd year of the Covid-19 pandemic, knowledge about the dynamics of the infection in the general population is still limited. Such information is essential for health planners, as many of those infected show no or only mild symptoms and thus, escape the surveillance system. We therefore aimed to describe the course of the pandemic in the Munich general population living in private households from April 2020 to January 2021.Methods The KoCo19 baseline study took place from April to June 2020 including 5313 participants (age 14 years and above). From November 2020 to January 2021, we could again measure SARS-CoV-2 antibody status in 4,433 of the baseline participants (response 83%). Participants were offered a self-sampling kit to take a capillary blood sample (dry blood spot; DBS). Blood was analysed using the Elecsys® Anti-SARS-CoV-2 assay (Roche). Questionnaire information on socio-demographics and potential risk factors assessed at baseline was available for all participants. In addition, follow-up information on health-risk taking behaviour and number of personal contacts outside the household (N=2768) as well as leisure time activities (N=1263) were collected in summer 2020.Results Weighted and adjusted (for specificity and sensitivity) SARS-CoV-2 sero-prevalence at follow-up was 3.6% (95% CI 2.9-4.3%) as compared to 1.8% (95% CI 1.3-3.4%) at baseline. 91% of those tested positive at baseline were also antibody-positive at follow-up. While sero-prevalence increased from early November 2021 to January 2021, no indication of geospatial clustering across the city of Munich was found, although cases clustered within households. Taking baseline result and time to follow-up into account, men and participants in the age group 20-34 years were at the highest risk of sero-positivity. In the sensitivity analyses, differences in health-risk taking behaviour, number of personal contacts and leisure time activities partly explained these differences.Conclusion The number of citizens in Munich with SARS-CoV-2 antibodies was still below 5% during the 2nd wave of the pandemic. Antibodies remained present in the majority of baseline participants. Besides age and sex, potentially confounded by differences in behaviour, no major risk factors could be identified. Non-pharmaceutical public health measures are thus still important.Competing Interest StatementThis study was funded by the Bavarian State Ministry of Science and the Arts, the University Hospital of Ludwig-Maximilians-University Munich, the Helmholtz Centre Munich, the University of Bonn, the University of Bielefeld, the European Unions Horizon 2020 research and innovation programme (ORCHESTRA Grant agreement ID: 101016167), Munich Center of Health (McHealth), the Deutsche Forschungsgesellschaft (SEPAN Grant number: HA 7376/3-1), Volkswagenstiftung (E2 Grant number: 99 450) and the German Ministry for Education and Research (MoKoCo19, reference number 01KI20271). Euroimmun, Mikrogen, Roche, and Viramed provided kits and machines for analyses at discounted rates. In addition, DM and VT are sub-investigators vaccines trials sponsored by Curevac AG. LO received non-financial support from Dr. Box Betrobox and grants from the Bavarian State Ministry of Science and the Arts during the conduct of the study. CR received royalities from Elsevier LTD for the textbook Clinical Cases in Tropical Medicine. She also received honoraria for lectures done at non-private academic institutions. CR is also chair of the Travel medicine board of the of the German Society for the Tropical Medicine, Travel Medicine and global health (unpaid) and member of the permanent committee on vaccinations at the Robert-Koch-Institute work group on travel vaccinations (unpaid). AW is on Roche Diagnostics and Roche Pharma Advisory Boards related SARS-CoV-2. The Bundeswehr Institute of Microbiology (RW) received research funding from the Medical Biodefence program of the Bundeswehr. The funders had no role in study design, data collection, data analyses, data interpretation, writing, or submission of this manuscript.Funding StatementThis study was funded by the Bavarian State Ministry of Science and the Arts, the University Hospital of Ludwig-Maximilians-University Munich, the Helmholtz Centre Munich, the University of Bonn, the University of Bielefeld, the European Unions Horizon 2020 research and innovation programme (ORCHESTRA Grant agreement ID: 101016167), Munich Center of Health (McHealth), the Deutsche Forschungsgesellschaft (SEPAN Grant number: HA 7376/3-1), Volkswagenstiftung (E2 Grant number: 99 450) and the German Ministry for Education and Research (MoKoCo19, reference number 01KI20271). Euroimmun, Mikrogen, Roche, and Viramed provided kits and machines for analyses at discounted rates. The funders had no role in study design, data collection, data analyses, data interpretation, writing, or submission of this manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted in accordance with good clinical (GCP) and epidemiological practice (GEP) standards as well as the Declaration of Helsinki in its most recent form (as amended by the 64th WMA General Assembly, Fortaleza, Brazil, in October 2013). The study protocol was approved by the Institutional Review Board of the Medical Faculty at Ludwig Maximilian University Munich, Germany (opinion dated 31 March 2020; number 20-275; opinion date amendment (follow-up): 10 October 2020), prior to study initiation.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are accessible subject to data protection regulations upon reasonable request to the corresponding author. To facilitate reproducibility and reuse, the analysis and figure generation code has been made available on GitHub (https://github.com/koco19/epi2) and has been uploaded to ZENODO (https://doi.org/10.5281/zenodo.4707037) for long-term storage.